Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Yosuke,Aoyama

第一单位： Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan.

作者： Yosuke,Aoyama ^[1] ; Yukinori,Ozaki ^[1] ; Rika,Kizawa ^[1] ; Jun,Masuda ^[1] ; Saori,Kawai ^[1] ; Mami,Kurata ^[1] ; Tetsuyo,Maeda ^[1] ; Kazuyo,Yoshida ^[1] ; Nami,Yamashita ^[1] ; Meiko,Nishimura ^[1] ; Mari,Hosonaga ^[1] ; Ippei,Fukada ^[1] ; Fumikata,Hara ^[1] ; Takayuki,Kobayashi ^[1] ; Toshimi,Takano ^[1] ; Takayuki,Ueno ^[2]

作者单位： Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan. ^[1] Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan. takayuki.ueno@jfcr.or.jp. ^[2]

关键词 ER-low HER2-negative tumor Pembrolizumab plus chemotherapy Triple-negative breast cancer

DOI 10.1007/s12282-024-01657-4

PMID 39644440

发布时间 2024-12-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Breast cancer (Tokyo, Japan)

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.

Breast cancer (Tokyo, Japan)

相似文献

Breast cancer (Tokyo, Japan)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.

Breast cancer (Tokyo, Japan)

相似文献

Breast cancer (Tokyo, Japan)

相关期刊

检索历史清除